Last reviewed · How we verify

Angelicin (sitosterol)

FDA-approved active ✓ Verified May 2026 Quality 17/100

Angelicin (generic name: sitosterol) is a sitosterol drug. It is currently FDA-approved.

Angelicin is a small molecule. It is a hydrophobic compound that is soluble in alcohols.

At a glance

Generic namesitosterol
Drug classsitosterol
TargetDNA polymerase beta, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B
Therapeutic areaHematology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Angelicin

What is Angelicin?

Angelicin (sitosterol) is a sitosterol drug.

What is the generic name of Angelicin?

sitosterol is the generic (nonproprietary) name of Angelicin.

What drug class is Angelicin in?

Angelicin belongs to the sitosterol class. See all sitosterol drugs at /class/sitosterol.

What development phase is Angelicin in?

Angelicin is FDA-approved (marketed).

What does Angelicin target?

Angelicin targets DNA polymerase beta, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B and is a sitosterol.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing